T16144 |
MRX-2843
|
1429882-07-4
|
99.51%
|
|
MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).
|
T17205 |
UNC2541
|
1612782-86-1
|
99.46%
|
|
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor. It also binds in the MerTK ATP pocket (IC50: 4.4 nM). UNC2541 inhibits phosphorylated Mer...
|
T6756 |
AMG 925
|
1401033-86-0
|
99.42%
|
|
AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.
|
T2066 |
Quizartinib
|
950769-58-1
|
99.42%
|
|
Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.
|
T3351 |
Onatasertib
|
1228013-30-6
|
99.41%
|
|
Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the i...
|
T73300 |
AXL-IN-13
|
2376928-82-2
|
99.38%
|
|
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 value of 1.6 nM and a Kd value of 0.26 nM.AXL-IN-13 exhibits anticancer activity, reverses TGF...
|
T2467 |
R406 free base
|
841290-80-0
|
99.31%
|
|
R406 free base (R406 (free base)) is a potent Syk inhibitor.
|
T2514 |
Linifanib
|
796967-16-3
|
99.29%
|
|
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDG...
|
T4209 |
TAK-659 hydrochloride
|
1952251-28-3
|
99.28%
|
|
TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most ot...
|
T3072 |
XL019
|
945755-56-6
|
99.23%
|
|
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.
|
T6479 |
Dovitinib lactate hydrate
|
915769-50-5
|
99.17%
|
|
Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM,...
|
T14779 |
BRD7389
|
376382-11-5
|
99.17%
|
|
BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.
|
T21503 |
(E/Z)-Zotiraciclib
|
937270-47-8
|
99.12%
|
|
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
|
T3078 |
SGI-1776
|
1025065-69-3
|
99.03%
|
|
SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.
|
T6138 |
TCS 359
|
301305-73-7
|
99.02%
|
|
TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.
|
T67754 |
JAK3-IN-14
|
454234-24-3
|
98.98%
|
|
JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
|
T11299 |
FLT3-IN-4
|
2304799-09-3
|
98.96%
|
|
FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous le...
|
T2605 |
Fostamatinib Disodium
|
1025687-58-4
|
98.95%
|
|
Fostamatinib Disodium (R788 Disodium) is an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities.
|
T4349 |
Sitravatinib
|
1123837-84-2
|
98.9%
|
|
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
|
T3065 |
TG101209
|
936091-14-4
|
98.81%
|
|
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
|